Last reviewed · How we verify
Fuzheng Huayu Tablets
Fuzheng Huayu Tablets is a traditional Chinese medicine formulation that promotes hepatic fibrosis reversal and liver function recovery through anti-inflammatory and antifibrotic pathways.
Fuzheng Huayu Tablets is a traditional Chinese medicine formulation that promotes hepatic fibrosis reversal and liver function recovery through anti-inflammatory and antifibrotic pathways. Used for Hepatic fibrosis and cirrhosis, Chronic hepatitis B with fibrosis, Liver fibrosis secondary to chronic liver disease.
At a glance
| Generic name | Fuzheng Huayu Tablets |
|---|---|
| Sponsor | Shanghai University of Traditional Chinese Medicine |
| Drug class | Herbal medicine / Traditional Chinese Medicine |
| Modality | Small molecule |
| Therapeutic area | Hepatology / Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
The herbal combination works by inhibiting hepatic stellate cell activation, reducing extracellular matrix deposition, and promoting apoptosis of activated fibroblasts. It also enhances immune function and reduces oxidative stress in liver tissue, supporting the body's natural ability to resolve existing fibrosis and restore normal hepatic architecture.
Approved indications
- Hepatic fibrosis and cirrhosis
- Chronic hepatitis B with fibrosis
- Liver fibrosis secondary to chronic liver disease
Common side effects
- Gastrointestinal upset
- Mild digestive discomfort
Key clinical trials
- Fuzheng Huayu Tablets Reduce the Occurrence of Re-Decompensation Events in Patients With First Decompensation of Hepatitis B-Related Liver Cirrhosis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study (NA)
- Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu (PHASE2)
- Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis (PHASE2)
- Effects of Fuzheng Huayu Tablets on COVID-19 (PHASE4)
- Treatment of Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir (PHASE4)
- Treatment of Moderate and Severe Cirrhotic Portal Hypertension Due to HBV With Fuzheng Huayu and Entecavir (PHASE4)
- Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir (PHASE4)
- Traditional Chinese Medicine Combined With Entecavir to Treat Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fuzheng Huayu Tablets CI brief — competitive landscape report
- Fuzheng Huayu Tablets updates RSS · CI watch RSS
- Shanghai University of Traditional Chinese Medicine portfolio CI